Lambda Integrase Landing Pads for Stable Eukaryotic Cell Lines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing biotherapeutics in mammalian cells, such as CHO and HEK293, face issues like genetic instability, immune response triggers, batch-to-batch variation, high costs, and difficulty in predicting consistent transgene expression, especially for human cell lines suitable for biopharmaceutical and biomedical applications.
Innovation Solution
A method for producing eukaryotic cells with a genomic landing pad for lambda integrase-mediated recombination, involving transfection of a bacterial plasmid with a modified lambda integrase recombination sequence and a fluorescent marker gene, followed by selection and isolation of cells with stable integration, enabling site-specific transgene insertion and stable expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If randomly integrated transgenes are used, then transgene expression can be achieved, but the process becomes costly and time-consuming due to screening of large number of clones
Solution Approach 1:
The patent creates a genomic landing pad with a pre-installed integrase recombination sequence at a specific genomic location before transgene insertion. This preliminary preparation of the integration site enables subsequent site-specific recombination, eliminating the need to screen numerous randomly integrated clones and significantly reducing the time and cost of producing stable cell lines.
2Productivity
If episomal transgenes are used, then high protein yields can be achieved, but batch-to-batch variation and yield depreciation occur with time
Solution Approach 1:
The patent establishes a stable genomic landing pad with integrase recombination sequence in the host cell genome before introducing the transgene. This preliminary integration of the recombination machinery into the genome ensures that subsequent transgene insertion occurs at a fixed, stable location, eliminating batch-to-batch variation and preventing yield depreciation over time while maintaining high protein yields.
3Ease of manufacture
If CHO cells are used for mass production, then cost-effective production is achieved, but genetic instability and immune response risks occur
Solution Approach 1:
The patent modifies the host cell system by introducing a specific genomic landing pad with integrase recombination sequence at a controlled genomic location. This parameter change from random integration to site-specific integration in human cells (such as HEK293) maintains cost-effectiveness while significantly improving genetic stability and eliminating immune response risks associated with CHO cell glycosylation patterns.
4Manufacturing precision
If site-specific transgene integration is used, then consistent transgene expression can be predicted, but the method requires complex genome engineering tools
Solution Approach 1:
The patent employs an integrase recombination sequence as an intermediary element that mediates between the transgene and the host cell genome. This intermediary landing pad with integrase sequence enables site-specific integration using simpler recombination mechanisms rather than complex CRISPR-Cas9 or other genome engineering tools, achieving high integration precision while reducing methodological complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the generation of stable, human eukaryotic cell lines with homogeneous and long-term transgene expression, facilitating efficient production of biotherapeutics and enabling applications in biopharmaceuticals and biomedical therapies.
Implementation Method 1
a method for production of a eukaryotic host cell or cell line for lambda-integrase-mediated recombination
Implementation Method 2
a first fluorescent marker gene, preferably mCherry, downstream of the modified lambda integrase recombination sequence
Data Source
AI summary
The present invention relates generally to the field of site-specific DNA recombination mediated by lambda integrases, and more specifically to methods of producing eukaryotic cells and cell lines comprising a genomic landing pad for lambda integrase mediated recombination, as well as the eukaryotic cells themselves and subsequent methods of their use for lambda integrase mediated recombination and as bioreactors for cell therapies.